Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 19.78% is in line with its 5-year average of 20.77%, around the middle of its 5-year range (17.13%–24.76%).
As of the fiscal period ended Tuesday, June 30, 2026. 8.49% below its 12-month average of 21.62%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
19.78%
EBITDA MARGIN AVG TTM
21.62%
EBITDA MARGIN AVG 3Y
21.22%
EBITDA MARGIN AVG 5Y
20.77%
EBITDA MARGIN AVG 10Y
21.10%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-8.49%
CURRENT VS 3Y AVG
-6.78%
CURRENT VS 5Y AVG
-4.75%
CURRENT VS 10Y AVG
-6.24%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Medpace Holdings, Inc.
Market Cap
$16.11B
EBITDA Margin
19.78%
TTM Avg
21.62%
3Y Avg
21.22%
5Y Avg
20.77%
Market Cap
$14.80B
EBITDA Margin
32.07%
TTM Avg
25.68%
3Y Avg
26.69%
5Y Avg
27.49%
Market Cap
$14.10B
EBITDA Margin
27.02%
TTM Avg
27.38%
3Y Avg
26.41%
5Y Avg
26.36%
Market Cap
$18.17B
EBITDA Margin
29.84%
TTM Avg
29.78%
3Y Avg
28.27%
5Y Avg
25.91%
Market Cap
$13.51B
EBITDA Margin
5.99%
TTM Avg
7.75%
3Y Avg
3.55%
5Y Avg
8.89%
Market Cap
$12.11B
EBITDA Margin
19.75%
TTM Avg
19.29%
3Y Avg
19.87%
5Y Avg
21.06%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $16.11B | 19.78% | 21.62% | 21.22% | 20.77% |
| DaVita Inc. (DVA)vs › | $15.41B | 19.98% | 20.97% | 19.78% | 20.10% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 24.73% | 27.15% | 30.37% | 35.33% |
| Solventum Corporation (SOLV)vs › | $14.80B | 32.07% | 25.68% | 26.69% | 27.49% |
| The Cooper Companies, Inc. (COO)vs › | $14.10B | 27.02% | 27.38% | 26.41% | 26.36% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.17B | 29.84% | 29.78% | 28.27% | 25.91% |
| Baxter International Inc. (BAX)vs › | $13.51B | 5.99% | 7.75% | 3.55% | 8.89% |
| Revvity, Inc. (RVTY)vs › | $12.55B | 23.07% | 26.75% | 30.05% | 32.80% |
| Align Technology, Inc. (ALGN)vs › | $12.11B | 19.75% | 19.29% | 19.87% | 21.06% |
| Viatris Inc. (VTRS)vs › | $20.45B | 0.95% | 10.32% | 17.98% | 18.96% |
Gross Margin
28.8%
EBITDA Margin
19.8%
Operating Margin
21.0%
Net Margin
17.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 19.78% |
| 2026-03-31 | 21.00% |
| 2025-12-31 | 22.64% |
| 2025-09-30 | 22.56% |
| 2025-06-30 | 22.10% |
| 2025-03-31 | 21.56% |
| 2024-12-31 | 24.76% |
| 2024-09-30 | 22.46% |
| 2024-06-30 | 21.28% |
| 2024-03-31 | 21.73% |
| 2023-12-31 | 18.92% |
| 2023-09-30 | 18.64% |
| 2023-06-30 | 18.42% |
| 2023-03-31 | 21.23% |
| 2022-12-31 | 20.89% |
| 2022-09-30 | 21.79% |
| 2022-06-30 | 18.73% |
| 2022-03-31 | 20.94% |
| 2021-12-31 | 19.55% |
| 2021-09-30 | 19.98% |
| 2021-06-30 | 17.13% |
| 2021-03-31 | 20.27% |
| 2020-12-31 | 23.29% |
| 2020-09-30 | 22.30% |
| 2020-06-30 | 16.97% |
| 2020-03-31 | 17.31% |
| 2019-12-31 | 18.03% |
| 2019-09-30 | 16.21% |
| 2019-06-30 | 18.79% |
| 2019-03-31 | 16.80% |
| 2018-12-31 | 21.04% |
| 2018-09-30 | 20.45% |
| 2018-06-30 | 19.37% |
| 2018-03-31 | 18.29% |
| 2017-12-31 | 23.99% |
| 2017-09-30 | 26.15% |
| 2017-06-30 | 26.21% |
| 2017-03-31 | 25.82% |
| 2016-12-31 | 25.42% |
| 2016-09-30 | 25.23% |
| 2016-06-30 | 26.97% |
| 2016-03-31 | 27.42% |
| 2015-12-31 | 14.47% |
| 2015-09-30 | 26.68% |
| 2015-06-30 | 30.10% |
| 2015-03-31 | 30.30% |
| 2014-03-31 | 11.38% |
